Intest Res.
2013 Oct;11(4):325-326. 10.5217/ir.2013.11.4.325.
The Efficacy of Vedolizumab, an alpha4beta7 Integrin Antibody, in Crohn's Disease and Ulcerative Colitis
- Affiliations
-
- 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Seoul, Korea. silverkes@naver.com
- KMID: 2284924
- DOI: http://doi.org/10.5217/ir.2013.11.4.325
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
- Emerging Therapies: What Are Promising in the Near Future?
- Pharmacologic treatment for inflammatory bowel disease
- Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
- Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
